| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
226,370,000 |
| Market
Cap: |
113.19(K) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.0001 - $1.63 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 542 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Invitae is engaged in the business of delivering genetic testing services, digital health solutions and health data services that support a lifetime of patient care from inherited disease diagnoses, to family planning, to proactive health screening to personalized diagnosis, treatment and monitoring of cancer. Testing and other services are delivered via a platform that serves patients, healthcare providers, biopharma companies and other partners. Co. applies proprietary design, process automation, robotics and bioinformatics software solutions to achieve efficiencies in sample processing and complex variant interpretation, allowing medical interpretation at scale.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
177,560 |
360,253 |
| Total Sell Value |
$0 |
$0 |
$249,954 |
$874,955 |
| Total People Sold |
0 |
0 |
5 |
6 |
| Total Sell Transactions |
0 |
0 |
7 |
21 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  George Sean E |
President & CEO |
• • – |
2021-01-21 |
4 |
AS |
$53.60 |
$466,703 |
D/D |
(8,675) |
637,343 |
|
-46% |
|
| George Sean E |
President & CEO |
• • – |
2021-01-21 |
4 |
OE |
$8.70 |
$43,500 |
D/D |
5,000 |
646,018 |
|
- |
|
| Stueland Katherine |
Chief Commercial Officer |
• – – |
2021-01-13 |
4 |
AS |
$48.50 |
$217,599 |
D/D |
(4,199) |
203,052 |
|
-44% |
|
| Stueland Katherine |
Chief Commercial Officer |
• – – |
2021-01-13 |
4 |
OE |
$10.94 |
$45,937 |
D/D |
4,199 |
207,251 |
|
- |
|
| Nussbaum Robert L |
Chief Medical Officer |
• – – |
2021-01-06 |
4 |
OE |
$9.90 |
$100,000 |
D/D |
10,101 |
225,312 |
|
- |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-24 |
4 |
AS |
$47.03 |
$2,349,262 |
D/D |
(48,971) |
410,597 |
|
-37% |
|
| Knight Kenneth D. |
Chief Operating Officer |
• – – |
2020-12-24 |
4 |
AS |
$50.50 |
$182,911 |
D/D |
(3,622) |
308,027 |
|
-37% |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-23 |
4 |
AS |
$51.54 |
$6,519,616 |
D/D |
(125,181) |
459,568 |
|
-39% |
|
| George Sean E |
President & CEO |
• • – |
2020-12-22 |
4 |
AS |
$51.62 |
$194,995 |
D/D |
(3,675) |
631,018 |
|
-41% |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-22 |
4 |
AS |
$51.73 |
$6,634,607 |
D/D |
(124,991) |
584,749 |
|
-41% |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-21 |
4 |
AS |
$47.10 |
$4,962,534 |
D/D |
(99,974) |
709,740 |
|
-34% |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-18 |
4 |
AS |
$47.39 |
$6,263,823 |
D/D |
(131,351) |
809,714 |
|
-27% |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
300,000 |
941,065 |
|
- |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-17 |
4 |
AS |
$46.64 |
$2,393,736 |
D/D |
(50,692) |
1,241,065 |
|
-26% |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-16 |
4 |
AS |
$47.32 |
$3,400,877 |
D/D |
(71,869) |
1,291,757 |
|
-28% |
|
| Aguiar Eric |
Director |
– • – |
2020-12-16 |
4 |
AS |
$50.74 |
$510,003 |
D/D |
(10,000) |
0 |
|
-28% |
|
| Aguiar Eric |
Director |
– • – |
2020-12-16 |
4 |
OE |
$24.16 |
$241,600 |
D/D |
10,000 |
10,000 |
|
- |
|
| Knight Kenneth D. |
Chief Operating Officer |
• – – |
2020-12-16 |
4 |
S |
$51.00 |
$680,901 |
D/D |
(13,351) |
311,649 |
|
28% |
|
| Myers Jason W. |
President, Oncology |
– • – |
2020-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
324,399 |
1,363,626 |
|
- |
|
| Stueland Katherine |
Chief Commercial Officer |
• – – |
2020-12-14 |
4 |
AS |
$54.57 |
$2,004,066 |
D/D |
(34,300) |
203,052 |
|
-30% |
|
| Werner Robert F. |
Chief Accounting Officer |
• – – |
2020-11-24 |
4 |
AS |
$46.91 |
$118,718 |
D/D |
(2,427) |
58,398 |
|
-20% |
|
| George Sean E |
President & CEO |
• – – |
2020-11-20 |
4 |
AS |
$46.85 |
$416,606 |
D/D |
(8,683) |
634,693 |
|
-16% |
|
| George Sean E |
President & CEO |
• – – |
2020-11-20 |
4 |
OE |
$8.70 |
$43,500 |
D/D |
5,000 |
643,376 |
|
- |
|
| Guyer Shelly D |
Chief Financial Officer |
• – – |
2020-11-18 |
4 |
AS |
$46.20 |
$140,264 |
D/D |
(3,000) |
224,520 |
|
-16% |
|
| Brida Thomas |
General Counsel |
• – – |
2020-11-17 |
4 |
AS |
$45.96 |
$230,052 |
D/D |
(5,000) |
207,876 |
|
-23% |
|
338 Records found
|
|
Page 6 of 14 |
|
|
0.01 (94.44%) 
